1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Legislation

Bill To Allow FDA To Destroy Counterfeit Devices Wins Praise On Hill; J&J Exec Testifies In Support

 
• By Sue Darcey

Several US House members are backing a new piece of legislation that would give the US Food and Drug Administration the authority to destroy counterfeit devices when they arrive at points of entry into the country. A Johnson & Johnson executive who specializes in global brand protection provided dramatic testimony before a House health panel on 29 January on the need for the anti-counterfeiting bill.

Capitol-building-dome-light

Medtech counterfeiters are endangering the lives of US patients with their illicit trade in counterfeit devices to American hospitals, and Congress could assist by giving the Food and Drug Administration the authority to destroy the fakes, a Johnson & Johnson executive says.

“Lawmakers play a critical role in strengthening our nation’s laws to reduce incentives for engaging in illegal trade. As such, Johnson & Johnson is very pleased to support H.R....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

More from Policy & Regulation

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By Ashley Yeo

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

Debate On FDA User Fee Reauthorization Begins To Take Shape

 
• By Elizabeth Orr

A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.